Welcome!

News Feed Item

Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017

NEW YORK, Jan. 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017

http://www.reportlinker.com/p01083061/Contrast-Media/Contrast-Agents-Market-By-Product-Iodinated-Gadolinium--Barium-By-Technique-X-ray-CT-MRI-Cath-Lab--Ultrasound--By-Application-Radiology-Interventional-Radiology--Interventional-Cardiology---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Contrast agents have evolved significantly over the past century, from barium and iodine-based agents that were used initially by medical practitioners and radiologists, to the more advanced agents like radiopharmaceuticals and gold nanoparticles that are currently in use. Sophisticated techniques such as targeted MRI imaging and gas microbubble technology in ultrasound will prove to be essential drivers in the widespread use of contrast agents in the future.

The global contrast media market is broadly segmented into barium-based, iodinated and gadolinium-based contrast media. These products are further categorized based on the medical procedure (X-ray, CT, MRI, ultrasound, and catheterization laboratory), route of administration (oral, injection, rectal, and urethral), medical indication (cardiovascular, respiratory, musculoskeletal, gastrointestinal, and neurology, nephrology and oncology) and finally application (radiology, interventional radiology and interventional cardiology). The global contrast media market is worth $6.2 billion in 2012, and estimated to grow at a CAGR of 6.8% to reach $8.6 billion by 2017.

The global contrast media market, though fairly mature at present (2012), still shows potential to grow over the next five years. It is propelled by the increasing demand for diagnostic imaging and image guided surgical procedures, technological advances in diagnostic imaging and the ever-increasing incidence rates of cancer and cardiac disorders. However, a few pivotal factors affecting the growth of this market are major economies of the world undergoing healthcare reforms, thereby affecting contrast media sales and the economic slowdown restricting the overall growth of this market.

The U.S. represents the largest contrast media market worldwide, followed by Europe and Japan. However, the economic slowdown has augmented opportunities for emerging markets like India and China to strengthen their position in the global arena. Advances in medical technology coupled with huge foreign investments from developed nations, allows these emerging markets to compete with global market leaders in this segment. Investment firms are increasingly focusing on expansion in developing markets of Asia, Latin America and Eastern Europe, since the U.S. is on the brink of embracing healthcare reforms and major economies in Europe are still recovering from huge financial deficits.

The global marketplace is highly competitive, with several small players specific to a particular geography challenging major ones. Owing to the recession and the emerging opportunities in developing countries, many small companies have similar product offerings at competitive prices. Some of the major players profiled in this report are GE Healthcare (U.K.), Bracco Diagnostic, Inc. (Italy), Bayer Healthcare Pharmaceuticals (Germany), Covidien (Ireland) and Guerbet Group (France).

The scope of the report spans the global contrast media market which comprises:

 

Global Contrast Media Market, by Product

Barium-based contrast media

Iodinated contrast media

Low-osmolar contrast media (LOCM)

High-osmolar contrast media (HOCM)

Gadolinium-based contrast media

Global Contrast Media Market, by Route of Administration

 

Oral

Injection

Intravenous (I.V.)

Intra-arterial (I.A.)

Rectal

Urethral

Global Contrast Media Market, by Medical Procedure

 

X-ray

Computed tomography (CT)

Magnetic resonance imaging (MRI)

Ultrasound

Catheterization laboratory (cath lab)

Global Contrast Media Market, by Indication

 

Cardiovascular disorders

Neurological disorders

Gastrointestinal disorders

Respiratory diseases

Musculoskeletal anomalies

Nephrological disorders

Oncology (tumor detection)

Global Contrast Media Market, by Application

 

Radiology

Interventional radiology

Interventional cardiology

Contrast Media Market, by Geography

 

North America

U.S.

Canada

Europe

United Kingdom (U.K.)

Germany

France

Italy

Spain

Scandinavian countries (Sweden, Denmark, Finland, and Norway)

Rest of Europe

Asia-Pacific (APAC)

Japan

China

India

Rest of Asia-Pacific

Rest of the world (RoW)

Latin America

Middle East & Africa

Russia

Each section of the report offers market data for the various market segments and geographies. It also provides in-depth information on market trends with respect to drivers, restraints, opportunities and technology trends.

 

TABLE OF CONTENTS

1 INTRODUCTION 21

1.1 KEY TAKE-AWAYS 21

1.2 REPORT DESCRIPTION 22

1.3 MARKETS COVERED 23

1.4 STAKEHOLDERS 26

1.5 RESEARCH METHODOLOGY 27

1.5.1 MARKET SIZE 27

1.5.2 MARKET SHARE 27

1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 27

1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 28

 

2 EXECUTIVE SUMMARY 29

 

3 MARKET OVERVIEW 33

3.1 INTRODUCTION 34

3.2 MARKET SEGMENTATION 35

3.3 MARKET DYNAMICS 36

3.3.1 DRIVERS 37

3.3.1.1 Increasing demand for diagnostic & image guided procedures influences contrast media sales 37

3.3.1.2 Technological advancements to spur the contrast media market 37

3.3.1.3 Increasing incidence & mortality of cancer & cardiac diseases to boost growth of contrast media 38

3.3.1.4 Growth of medical imaging technology in emerging markets 38

3.3.2 RESTRAINTS 39

3.3.2.1 Major economies undergoing healthcare reforms to affect the sales on contrast media 39

3.3.2.2 Economic slowdown to inhibit growth 40

3.3.3 OPPORTUNITIES 41

3.3.3.1 Growing investment potential in immature emerging markets 41

3.3.3.2 Advent of novel contrast agents combining properties of contrast media & radiopharmaceuticals 41

3.3.4 BURNING ISSUE - TOXICITY 42

3.3.4.1 Nephrogenic systemic fibrosis (NSF) 42

3.3.4.2 Contrast-induced nephrotoxicity (CIN) 43

3.3.5 TECHNOLOGY TRENDS 44

3.3.5.1 N1177 – A revolutionary macrophage labeling agent 44

3.3.5.2 SPAGO Pix – Accurate visualization of tumors with MRI 46

3.3.5.3 CMC-001 – Focused on liver MRI 46

3.4 MARKET SHARE ANALYSIS 47

 

4 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT 50

4.1 INTRODUCTION 51

4.2 BARIUM-BASED CONTRAST MEDIA 55

4.2.1 TECHNICAL OVERVIEW 55

4.2.2 MARKET DYNAMICS 56

4.2.3 MARKET ANALYSIS 56

4.3 IODINATED CONTRAST MEDIA 58

4.3.1 TECHNICAL OVERVIEW 58

4.3.2 MARKET DYNAMICS 58

4.3.3 MARKET ANALYSIS 59

4.3.4 TYPES – LOW-OSMOLAR AND HIGH-OSMOLAR 61

4.3.4.1 Low-osmolar contrast media (LOCM) 61

4.3.4.1.1 Technical overview 61

4.3.4.1.2 Market analysis 63

4.3.4.2 High-osmolar contrast media (HOCM) 64

4.3.4.2.1 Technical overview 64

4.3.4.2.2 Market analysis 65

4.4 GADOLINIUM-BASED CONTRAST MEDIA 66

4.4.1 TECHNICAL OVERVIEW 66

4.4.2 MARKET DYNAMICS 67

4.4.3 MARKET ANALYSIS 67

 

5 GLOBAL CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION 69

5.1 INTRODUCTION 70

5.2 ORAL CONTRAST MEDIA 73

5.2.1 TECHNICAL OVERVIEW 73

5.2.2 MARKET DYNAMICS 73

5.2.3 MARKET ANALYSIS 74

5.3 INJECTABLE CONTRAST MEDIA 75

5.3.1 TECHNICAL OVERVIEW 75

5.3.2 MARKET DYNAMICS 76

5.3.3 MARKET ANALYSIS 77

5.3.4 INJECTABLE CONTRAST MEDIA – TYPES 78

5.3.4.1 Intravenous (IV) 78

5.3.4.2 Intra-Arterial (IA) 79

5.4 RECTAL CONTRAST MEDIA 81

5.4.1 TECHNICAL OVERVIEW 81

5.4.2 MARKET DYNAMICS 81

5.4.3 MARKET ANALYSIS 82

5.5 URETHRAL CONTRAST MEDIA 83

5.5.1 TECHNICAL OVERVIEW 83

5.5.2 MARKET DYNAMICS 83

5.5.3 MARKET ANALYSIS 84

 

6 GLOBAL CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE 86

6.1 INTRODUCTION 87

6.2 X-RAY 89

6.2.1 TECHNICAL OVERVIEW 89

6.2.2 MARKET DYNAMICS 90

6.2.3 MARKET ANALYSIS 91

6.3 COMPUTED TOMOGRAPHY (CT) 92

6.3.1 TECHNICAL OVERVIEW 92

6.3.2 MARKET DYNAMICS 93

6.3.3 MARKET ANALYSIS 93

6.4 MAGNETIC RESONANCE IMAGING (MRI) 94

6.4.1 TECHNICAL OVERVIEW 94

6.4.2 MARKET DYNAMICS 95

6.4.3 MARKET ANALYSIS 96

6.5 ULTRASOUND 97

6.5.1 TECHNICAL OVERVIEW 97

6.5.2 MARKET DYNAMICS 97

6.5.3 MARKET ANALYSIS 98

6.6 CATHETERIZATION LABORATORY (CATH LAB) 99

6.6.1 TECHNICAL OVERVIEW 99

6.6.2 MARKET DYNAMICS 100

6.6.3 MARKET ANALYSIS 101

 

7 GLOBAL CONTRAST MEDIA MARKET, BY INDICATION 102

7.1 INTRODUCTION 103

7.2 CARDIOVASCULAR DISORDERS 105

7.2.1 MARKET DYNAMICS 105

7.2.2 MARKET ANALYSIS 106

7.3 NEUROLOGICAL DISORDERS 107

7.3.1 MARKET DYNAMICS 107

7.3.2 MARKET ANALYSIS 107

7.4 RESPIRATORY DISEASES 109

7.4.1 MARKET DYNAMICS 109

7.4.2 MARKET ANALYSIS 109

7.5 GASTROINTESTINAL DISORDERS 111

7.5.1 MARKET DYNAMICS 111

7.5.2 MARKET ANALYSIS 111

7.6 ONCOLOGY 113

7.6.1 MARKET DYNAMICS 113

7.6.2 MARKET ANALYSIS 113

7.7 MUSCULOSKELETAL ANOMALIES 115

7.7.1 MARKET DYNAMICS 115

7.7.2 MARKET ANALYSIS 116

7.8 NEPHROLOGICAL DISORDERS 117

7.8.1 MARKET DYNAMICS 117

7.8.2 MARKET ANALYSIS 117

 

8 GLOBAL CONTRAST MEDIA MARKET, BY APPLICATION 119

8.1 INTRODUCTION 120

8.2 RADIOLOGY 123

8.2.1 TECHNICAL OVERVIEW 123

8.2.2 MARKET DYNAMICS 123

8.2.3 MARKET ANALYSIS 124

8.3 INTERVENTIONAL RADIOLOGY 126

8.3.1 TECHNICAL OVERVIEW 126

8.3.2 MARKET DYNAMICS 126

8.3.3 MARKET ANALYSIS 127

8.4 INTERVENTIONAL CARDIOLOGY 129

8.4.1 TECHNICAL OVERVIEW 129

8.4.2 MARKET DYNAMICS 130

8.4.3 MARKET ANALYSIS 130

 

9 GEOGRAPHIC ANALYSIS 132

9.1 INTRODUCTION 133

9.2 NORTH AMERICA 134

9.3 EUROPE 143

9.4 ASIA-PACIFIC 152

9.5 REST OF THE WORLD (ROW) 161

 

10 COMPETITIVE LANDSCAPE 169

10.1 INTRODUCTION 169

10.2 MERGERS & ACQUISITIONS 172

10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 174

10.4 NEW PRODUCT LAUNCH 178

10.5 EXPANSION 180

10.6 APPROVALS 182

10.7 OTHER DEVELOPMENTS 184

 

11 COMPANY PROFILES 187

11.1 AMAG PHARMACEUTICALS, INC. 195

11.2 BAYER HEALTHCARE PHARMACEUTICALS 199

11.3 BRACCO IMAGING SPA (A SUBSIDIARY OF BRACCO S.P.A) 209

11.4 COVIDIEN 213

11.5 CMC CONTRAST AB 220

11.6 DAIICHI SANKYO CO., LTD. 222

11.7 GE HEALTHCARE 228

11.8 GENOVIS AB 235

11.9 GUERBET GROUP 240

11.10 LANTHEUS MEDICAL IMAGING, INC. 247

11.11 NANOPET PHARMA GMBH 254

11.12 NANOSCAN IMAGING, LLC 258

11.13 SANOCHEMIA PHARMAZEUTIKA AG 260

11.14 SPAGO IMAGING AB (A SUBSIDIARY OF ACCELERATOR NORDIC AB) 267

11.15 SUBHRA PHARMA PRIVATE, LTD 271

11.16 TAEJOON PHARM CO., LTD. 274

11.17 TARGESON, INC. 278

11.18 UNIJULES LIFE SCIENCES, LTD. 283

 

LIST OF TABLES

TABLE 1 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT,

2010 – 2017 ($MILLION) 30

TABLE 2 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 32

TABLE 3 CLASSIFICATION OF GBCAS BY U.S. FDA BASED ON NUMBER OF NSF CASES 43

TABLE 4 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY PRODUCT,

2010 - 2017 ($MILLION) 52

TABLE 5 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 53

TABLE 6 BARIUM-BASED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010-2017 ($MILLION) 57

TABLE 7 IODINATED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 60

TABLE 8 IODINATED CONTRAST MEDIA MARKET REVENUE, BY TYPE,

2010 - 2017 ($MILLION) 61

TABLE 9 IODINATED-LOCM CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 63

TABLE 10 IODINATED-HOCM CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 65

TABLE 11 GADOLINIUM-BASED CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 - 2017 ($MILLION) 68

TABLE 12 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 71

TABLE 13 ORAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 75

TABLE 14 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 77

TABLE 15 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,

2010 – 2017 ($MILLION) 78

TABLE 16 INTRAVENOUS INJECTABLE CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 79

TABLE 17 INTRA-ARTERIAL INJECTABLE CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 80

TABLE 18 RECTAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 82

TABLE 19 URETHRAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 85

TABLE 20 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION) 88

TABLE 21 X-RAY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 91

TABLE 22 CT CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 94

TABLE 23 MRI CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 96

TABLE 24 ULTRASOUND CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 98

TABLE 25 CATH LAB CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 101

TABLE 26 GLOBAL CONTRAST MEDIA MARKET, BY INDICATION,

2010 – 2017 ($MILLION) 104

TABLE 27 CARDIOVASCULAR DISEASES - CONTRAST MEDIA MARKET,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 106

TABLE 28 NEUROLOGICAL DISORDERS - CONTRAST MEDIA MARKET,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 108

TABLE 29 RESPIRATORY DISEASES - CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 110

TABLE 30 GASTROINTESTINAL DISORDERS - CONTRAST MEDIA MARKET,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 112

TABLE 31 ONCOLOGY - CONTRAST MEDIA MARKET, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 114

TABLE 32 MUSCULOSKELETAL ANOMALIES – CONTRAST MEDIA MARKET,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 116

TABLE 33 NEPHROLOGICAL DISORDERS - CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 118

TABLE 34 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY APPLICATION,

2010 – 2017 ($MILLION) 122

TABLE 35 RADIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 125

TABLE 36 INTERVENTIONAL RADIOLOGY CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 128

TABLE 37 INTERVENTIONAL CARDIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 131

TABLE 38 CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 133

TABLE 39 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY,

2010 – 2017 ($MILLION) 135

TABLE 40 NORTH AMERICA: CONTRAST MEDIA MARKET, BY PRODUCT,

2010 – 2017 ($MILLION) 136

TABLE 41 NORTH AMERICA: IODINATED CONTRAST MEDIA MARKET, BY TYPE, 2010 – 2017 ($MILLION) 137

TABLE 42 NORTH AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION,

2010 – 2017 ($MILLION) 138

TABLE 43 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INDICATION,

2010 – 2017 ($MILLION) 139

TABLE 44 NORTH AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 140

TABLE 45 NORTH AMERICA: INJECTABLE CONTRAST MEDIA MARKET,

BY TYPE, 2010 – 2017 ($MILLION) 141

TABLE 46 NORTH AMERICA: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION) 142

TABLE 47 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY,

2010 – 2017 ($MILLION) 144

TABLE 48 EUROPE: CONTRAST MEDIA MARKET, BY PRODUCT,

2010 – 2017 ($MILLION) 145

TABLE 49 EUROPE: IODINATED CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 146

TABLE 50 EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION,

2010 – 2017 ($MILLION) 147

TABLE 51 EUROPE: CONTRAST MEDIA MARKET, BY INDICATION,

2010 – 2017 ($MILLION) 148

TABLE 52 EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 149

TABLE 53 EUROPE: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 150

TABLE 54 EUROPE: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE,

2010 – 2017 ($MILLION) 151

TABLE 55 APAC: CONTRAST MEDIA MARKET, BY COUNTRY,

2010 – 2017 ($MILLION) 153

TABLE 56 APAC: CONTRAST MEDIA MARKET, BY PRODUCT,

2010 – 2017 ($MILLION) 154

TABLE 57 APAC: IODINATED CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 155

TABLE 58 APAC: CONTRAST MEDIA MARKET, BY APPLICATION,

2010 – 2017 ($MILLION) 156

TABLE 59 APAC: CONTRAST MEDIA MARKET, BY INDICATION,

2010 – 2017 ($MILLION) 157

TABLE 60 APAC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 158

TABLE 61 APAC: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 159

TABLE 62 APAC: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE,

2010 – 2017 ($MILLION) 160

TABLE 63 ROW: CONTRAST MEDIA MARKET REVENUE, BY REGION,

2010 – 2017 ($MILLION) 161

TABLE 64 ROW: CONTRAST MEDIA MARKET REVENUE, BY PRODUCT,

2010 – 2017 ($MILLION) 162

TABLE 65 ROW: IODINATED CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 163

TABLE 66 ROW: CONTRAST MEDIA MARKET REVENUE, BY APPLICATION,

2010 – 2017 ($MILLION) 164

TABLE 67 ROW: CONTRAST MEDIA MARKET REVENUE, BY INDICATION,

2010 – 2017 ($MILLION) 165

TABLE 68 ROW: CONTRAST MEDIA MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 166

TABLE 69 ROW: INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,

2010 – 2017 ($MILLION) 167

TABLE 70 ROW: CONTRAST MEDIA MARKET REVENUE, BY MEDICAL PROCEDURE,

2010 – 2017 ($MILLION) 168

TABLE 71 MERGERS & ACQUISITIONS, 2010 – 2012 172

TABLE 72 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2012 174

TABLE 73 NEW PRODUCT LAUNCH, 2010 – 2012 178

TABLE 74 EXPANSION, 2010 – 2012 180

TABLE 75 APPROVALS, 2010 – 2012 182

TABLE 76 OTHER DEVELOPMENTS, 2010 – 2012 184

TABLE 77 AMAG PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES,

2009 – 2011 ($MILLION) 196

TABLE 78 AMAG PHARMACEUTICALS: TOTAL REVENUE, BY SEGMENT,

2009 – 2011 ($MILLION) 197

TABLE 79 AMAG PHARMACEUTICALS: TOTAL PRODUCT SALES, BY PRODUCT, 2009 – 2011 ($MILLION) 197

TABLE 80 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 200

TABLE 81 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,

BY SEGMENT, 2009 – 2011 ($MILLION) 201

TABLE 82 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,

BY GEOGRAPHY, 2009 – 2011 ($MILLION) 202

TABLE 83 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY DIVISION, 2009 – 2011 ($MILLION) 203

TABLE 84 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 203

TABLE 85 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY SEGMENT, 2009 - 2011 ($MILLION) 204

TABLE 86 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY GEOGRAPHY,

2009 – 2011 ($MILLION) 205

TABLE 87 COVIDIEN: NET SALES AND R&D EXPENSES, 2009 – 2011 ($MILLION) 214

TABLE 88 COVIDIEN: NET SALES, BY SEGMENTS, 2009 – 2011 ($MILLION) 215

TABLE 89 COVIDIEN: NET SALES, BY PHARMACEUTICAL PRODUCTS,

2009 – 2011 ($MILLION) 216

TABLE 90 COVIDIEN: NET SALES, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 217

TABLE 91 DAIICHI SANKYO CO., LTD.: NET SALES AND R&D EXPENSES,

2009 – 2011 ($BILLION) 223

TABLE 92 DAIICHI SANKYO CO., LTD.: NET SALES, BY GEOGRAPHY,

2009 – 2011 ($MILLION) 224

TABLE 93 GENERAL ELECTRIC: TOTAL REVENUE AND R&D EXPENSES,

2009 – 2011 ($BILLION) 229

TABLE 94 GENERAL ELECTRIC: TOTAL REVENUE, BY SEGMENTS,

2009 – 2011 ($BILLION) 229

TABLE 95 GENERAL ELECTRIC: TOTAL REVENUE, BY GEOGRAPHY,

2009 – 2011 ($BILLION) 230

TABLE 96 GENOVIS AB: TOTAL REVENUE AND R&D EXPENSES,

2010 – 2012 ($THOU.S.ND) 236

TABLE 97 GENOVIS AB: TOTAL REVENUE, BY GEOGRAPHY,

2010 – 2012 ($THOU.S.ND) 236

TABLE 98 GUERBET: TOTAL REVENUE AND R&D EXPENSES,

2010 – 2012 ($MILLION) 241

TABLE 99 GUERBET: TOTAL REVENUE, BY PRODUCTS, 2010 – 2012 ($MILLION) 242

TABLE 100 GUERBET: TOTAL REVENUE, BY GEOGRAPHY 2010 – 2012 ($MILLION) 243

TABLE 101 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 248

TABLE 102 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 248

TABLE 103 LANTHEUS : TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 249

TABLE 104 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 261

TABLE 105 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2011 ($MILLION) 262

TABLE 106 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 263

TABLE 107 ACCELERATOR NORDIC AB: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($THOU.S.ND) 268

 

LIST OF FIGURES

FIGURE 1 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 31

FIGURE 2 CONTRAST MEDIA MARKET SEGMENTATION 35

FIGURE 3 MARKET DYNAMICS 36

FIGURE 4 GLOBAL CONTRAST MEDIA MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2011 48

FIGURE 5 CONTRAST MEDIA MARKET SEGMENTATION, BY PRODUCT 51

FIGURE 6 CHEMISTRY OF LOW OSMOLAR CONTRAST MEDIA (LOCM) 62

FIGURE 7 CHEMISTRY OF HIGH-OSMOLAR CONTRAST MEDIA (HOCM) 64

FIGURE 8 CONTRAST MEDIA MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION 70

FIGURE 9 CONTRAST MEDIA MARKET SEGMENTATION, BY MEDICAL PROCEDURE 87

FIGURE 10 CONTRAST MEDIA MARKET SEGMENTATION, BY INDICATION 103

FIGURE 11 CONTRAST MEDIA MARKET SEGMENTATION, BY APPLICATION 121

FIGURE 12 KEY GROWTH STRATEGIES, 2010 – 2012 169

FIGURE 13 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES STRATEGY, 2010 – 2012 170

FIGURE 14 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY,

2010 – 2012 171

 

To order this report:

Medical_Imaging Industry: Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists l...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
MongoDB Atlas leverages VPC peering for AWS, a service that allows multiple VPC networks to interact. This includes VPCs that belong to other AWS account holders. By performing cross account VPC peering, users ensure networks that host and communicate their data are secure. In his session at 20th Cloud Expo, Jay Gordon, a Developer Advocate at MongoDB, will explain how to properly architect your VPC using existing AWS tools and then peer with your MongoDB Atlas cluster. He'll discuss the secur...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service.
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
In his session at Cloud Expo, Alan Winters, an entertainment executive/TV producer turned serial entrepreneur, will present a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to max...
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...